ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Context Therapeutics Inc

Context Therapeutics Inc (CNTX)

1.38
-0.002
(-0.14%)
Closed March 29 04:00PM
1.37
-0.01
(-0.72%)
After Hours: 07:59PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
1.38
Bid
1.32
Ask
1.46
Volume
56,044
1.38 Day's Range 1.49
0.47 52 Week Range 1.69
Market Cap
Previous Close
1.382
Open
1.38
Last Trade
15
@
1.37
Last Trade Time
Financial Volume
$ 79,676
VWAP
1.4217
Average Volume (3m)
45,190
Shares Outstanding
15,966,053
Dividend Yield
-
PE Ratio
-1.45
Earnings Per Share (EPS)
-0.96
Revenue
-
Net Profit
-15.34M

About Context Therapeutics Inc

Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and ... Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Context Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CNTX. The last closing price for Context Therapeutics was $1.38. Over the last year, Context Therapeutics shares have traded in a share price range of $ 0.47 to $ 1.69.

Context Therapeutics currently has 15,966,053 shares outstanding. The market capitalization of Context Therapeutics is $22.19 million. Context Therapeutics has a price to earnings ratio (PE ratio) of -1.45.

CNTX Latest News

Context Therapeutics Reports Full Year 2023 Operating and Financial Results

CTIM-76 IND filing on track for late March 2024 Cash and cash equivalents of $14.4 million as of December 31, 2023 Company expects its cash and cash equivalents will continue to fund operations...

Form 8-K - Current report

0001842952FALSE00018429522024-02-292024-02-29UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549_______________________FORM 8-K_______________________CURRENT REPORTPursuant to...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549SCHEDULE 13GUnder the Securities Exchange Act of 1934(Amendment No. 1)*Context Therapeutics Inc.(Name of Issuer)Common Stock...

Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results

CTIM-76 IND filing on track for late Q1 2024 Cash and cash equivalents of $21.7 million as of September 30, 2023 Company expects its cash and cash equivalents will continue to fund operations...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

FALSE2023Q3000184295212-3100018429522023-01-012023-09-3000018429522023-11-06xbrli:shares00018429522023-09-30iso4217:USD00018429522022-12-31iso4217:USDxbrli:shares00018429522023-07-012023-09-3000018...

Form 8-K - Current report

0001842952FALSE00018429522023-10-312023-10-31UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549_______________________FORM 8-K_______________________CURRENT REPORTPursuant to...

Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76

CTIM-76 exhibits dose-proportional tumor responses and safety in preclinical models Benchmarking studies comparing CTIM-76 with clinical-stage CLDN6 therapies support CTIM-76's differentiated...

Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

PHILADELPHIA, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.2218.96551724141.161.491.061486391.25485471CS
40.2117.94871794871.171.491.03748511.19867377CS
120.229219.91657977061.15081.490.89451901.16508762CS
260.021.470588235291.361.520.77462731.15461142CS
520.77126.2295081970.611.690.47747801.03825531CS
156-3.06-68.91891891894.4410.870.478504533.94842388CS
260-3.06-68.91891891894.4410.870.478504533.94842388CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 22.08
(364.84%)
31.9M
NXLNexalin Technologies Inc
$ 1.50
(92.31%)
11.67M
CEROCERo Therapeutics Holdings Inc
$ 3.112
(90.92%)
24.08M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
KYCHKeyarch Acquisition Corporation
$ 12.30
(75.58%)
196.62k
BOLDBoundless Bio Inc
 14.25
(-76.24%)
767.63k
PMECPrimech Holdings Ltd
$ 1.2999
(-66.50%)
8.28M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.1816
(-44.45%)
21.92M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
NKLANikola Corporation
$ 1.035
(13.85%)
163.84M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
MARAMarathon Digital Holdings Inc
$ 22.56
(2.22%)
86.14M
AKANAkanda Corporation
$ 0.1166
(-29.29%)
80.34M

CNTX Discussion

View Posts
BurgerKing82 BurgerKing82 1 month ago
No one has posted here in over 4 monthes...thoughts here?
🤡 1
Biorat Biorat 6 months ago
Updated Information

Should Investors Be Buying Context Therapeutics (CNTX)?

(Take a look at CONTEXT Therapeutics) CTIM-76 a CLDN6 antagonist that's in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This selective binding allows CTIM-76 to redirect T-cell activation away from where it would be harmful and enhances the safety profile vs its peers. There is an immense market given the absolute need for a high specificity to solid tumor cell treatment. $6.25-$15 a share is reasonable within 12 months. The upcoming Society for Immunotherapy of Cancer meeting may alert investors to a potential blockbuster. CNTX shares could easily climb multiples higher given the tightly held float. By the time investors realize CTIM-76 is an exceptionally attractive investment CNTX shares will likely be trading over $4 a share and heading higher. At the point clinical trials start showing their results be prepared to pony up for shares. There is now an opportunity to invest in CNTX before the bulk of investors come up to speed concerning the potential market value of a pending CTIM-76 blockbuster. There are also other irons in the fire at Context Therapeutics to maintain shareholder excitement as well.  Currently they are on the back burner due to prioritization.

Onapristine is one example of an iron in the fire even if it seems to be on hold for now. 

As stated by Context Therapeutics they will "explore strategic options for Onapristine-XR." This leaves the possibility of a joint venture concerning Onapristine or sale of Onapristine outright. Due to elevated liver function tests identified in three patients, including in one patient who discontinued treatment, although NONE of the elevated LFTs were considered serious adverse events. The Company determined that significant incremental program costs and delays were likely to be required.  Context is a small entity. Cost is the reason the Oath trial is on hold not a failure.
Investors should look up the Onapristine ER trial (Oath) in the Journal of Clinical Oncology.

Why the focus is on CTIM-76 vs Onapristine even though Onapristine has value? The company see's a better path.

It's been found that CTIM-76 is more specific at binding to the desired target CLDN6 than Amgen's candidate AMG 794 Therefore it's possible CTIM-76 gets a collaboration offer or buyout offer that's large. Amgen knows it & here's why. CTIM-76 is found to be approximately 28 times more potent than a competing approach utilizing a bispecific T-cell engager (BITE) format. Don't overlook; Astellas acquired Ganymed & gains access to mAbs targeting CLDN6 (IMAB027) & CLDN18.2 (IMAB362)... CTIM-76 is thought to have more value in treating cancers.

Right now the shares of CNTX are held tight and likely have only a small pool available. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock as a buy. There is a growing consensus among some investors that the forecast is far to conservative with a $6.25-$15 range seeming a more realistic target within a year. Do some homework and see the opportunity before the masses. Like other biotech stocks, share value tends to get heated early when showing potential like this. Don't believe it? Look over Viking Therapeutics (VKTX) where it traded under $2 a share. CNTX isn't different; it's poised for the same type of breakout. Those Looking at the 5 year chart will have their eyes opened.

Investors should not forget Context Therapeutics announced on December 6, 2021 it had closed a previously announced placement of 5 million shares at a price of $6.25 per share. ThinkEquity acted as the sole placement agent and had no problem finding placement of those shares. There's a reason for that and that reason has not changed. The beat down of the share price is now over and referring back to Viking Therapeutics it had the same beat down before running up to over $25 a share. In fact on September 16, 2018 VKTX shares traded at $18.20 at the close of the day before being beaten down to $2.23 a share on June 5, 2022 only to break out and run to $24.27 on June 4, 2023. Even before that on July 30, 2017 VKTX shares closed at a mere 98 cents. The proven way to invest is buying in after the beatdown has occurred and when the facts on the ground for that investment have not changed. If you have invested that way you have better odds at picking a winner.

Concerning the science, CLDN6 differs from other claudins in that it's present in a mothers womb during a baby's development. After development CLDN6 is turned off. Cancer turns back on this claudin 6 to grow. CTIM-76 in development by CONTEXT Therapeutics attacks the turned on CLDN6. CTIM-76 is very specific at targeting CLND6. Other claudins exist that are needed in the body and targeting them could be harmful such as claudin 9 that is needed for hearing.

This isn't anything other than my own research and investors must do their own before making a wise decision.
👍️0
Biorat Biorat 6 months ago
Should Investors Be Buying Context Therapeutics (CNTX)?

(Take a look at CONTEXT Therapeutics) CTIM-76 a CLDN6 antagonist that's in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This selective binding allows CTIM-76 to redirect T-cell activation away from where it would be harmful and enhances the safety profile vs its peers. There is an immense market given the absolute need for a high specificity to solid tumor cell treatment. $6.25-$15 a share is reasonable within 12 months. The upcoming Society for Immunotherapy of Cancer meeting may alert investors to a potential blockbuster. CNTX shares could easily climb multiples higher given the tightly held float. By the time investors realize CTIM-76 is an exceptionally attractive investment CNTX shares will likely be trading over $4 a share and heading higher. At the point clinical trials start showing their results be prepared to pony up for shares. There is now an opportunity to invest in CNTX before the bulk of investors come up to speed concerning the potential market value of a pending CTIM-76 blockbuster. There are also other irons in the fire at Context Therapeutics to maintain shareholder excitement as well.  Currently they are on the back burner due to prioritization.  

One such example investors should look up is the Onapristine ER trial (Oath) in the Journal of Clinical Oncology.  Oath trial

Below is why the focus is on CTIM-76 vs Onapristine even though it has value

It's been found that CTIM-76 is more specific @ binding to the desired target CLDN6 than Amgen's candidate AMG 794 Therefore it's possible CTIM-76 gets a collaboration offer or buyout offer that's large. Amgen knows it & here's why. CTIM-76 is found to be approximately 28 times more potent than a competing approach utilizing a bispecific T-cell engager (BITE) format. Don't overlook; Astellas acquired Ganymed & gains access to mAbs targeting CLDN6 (IMAB027) & CLDN18.2 (IMAB362)... CTIM-76 is thought to have more value in treating cancers.

Right now the shares of CNTX are held tight and likely have only a small pool available. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock as a buy. There is a growing consensus among some investors that the forecast is far to conservative with a $6.25-$15 range seeming a more realistic target within a year. Do some homework and see the opportunity before the masses. Like other biotech stocks, share value tends to get heated early when showing potential like this. Don't believe it? Look over Viking Therapeutics (VKTX) where it traded under $2 a share. CNTX isn't different; it's poised for the same type of breakout. Those Looking at the 5 year chart will have their eyes opened.

Investors should not forget Context Therapeutics announced on December 6, 2021 it had closed a previously announced placement of 5 million shares at a price of $6.25 per share. ThinkEquity acted as the sole placement agent and had no problem finding placement of those shares. There's a reason for that and that reason has not changed. The beat down of the share price is now over and referring back to Viking Therapeutics it had the same beat down before running up to over $25 a share. In fact on September 16, 2018 VKTX shares traded at $18.20 at the close of the day before being beaten down to $2.23 a share on June 5, 2022 only to break out and run to $24.27 on June 4, 2023. Even before that on July 30, 2017 VKTX shares closed at a mere 98 cents. The proven way to invest is buying in after the beatdown has occurred and when the facts on the ground for that investment have not changed. If you have invested that way you have better odds at picking a winner.

Concerning the science, CLDN6 differs from other claudins in that it's present in a mothers womb during a baby's development. After development CLDN6 is turned off. Cancer turns back on this claudin 6 to grow. CTIM-76 in development by CONTEXT Therapeutics attacks the turned on CLDN6. CTIM-76 is very specific at targeting CLND6. Other claudins exist that are needed in the body and targeting them could be harmful such as claudin 9 that is needed for hearing.

This isn't anything other than my own research and investors must do their own before making a wise decision.
👍️0
richme richme 6 months ago
For new or old investors consider wanting to come in please follow the tracks of some very recent posts and it will lead you to several stocks that, in my opinion, were manipulated (milked) for big bucks then stopped posting in those Boards. I can provide the stocks and the
"investors" involved if you PM me.
👍️0
Biorat Biorat 6 months ago
Whether It’s Cloudy Or Sunny, You Should Be Buying Context Therapeutics (CNTX)

Oct. 3, 2023 4:39 PM ET| About: Context Therapeutics Inc. (CNTX), Includes: VKTX

Biotech Rat

Value, Special Situations, Momentum, Long/Short Equity

Summary
CTIM-76, a CLDN6 antagonist developed by Context Therapeutics, shows promise in redirecting T-cell activation towards tumor cells, enhancing safety.

The upcoming Society for Immunotherapy of Cancer meeting may highlight CTIM-76 as a potential blockbuster, leading to a surge in CNTX shares.

Analysts predict a conservative $4 a share or 164.90% increase in CNTX stock within 12 months, with a more realistic target range of $6.25-$15 explained here.

(Take a look at CONTEXT Therapeutics) CTIM-76 a CLDN6 antagonist that's in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This selective binding allows CTIM-76 to redirect T-cell activation away from where it would be harmful and enhances the safety profile vs its peers. There is an immense market given the absolute need for a high specificity to solid tumor cell treatment. $6.25-$15 a share is reasonable within 12 months. The upcoming Society for Immunotherapy of Cancer meeting may alert investors to a potential blockbuster. CNTX shares could easily climb multiples higher given the tightly held float. By the time investors realize CTIM-76 is an exceptionally attractive investment CNTX shares will likely be trading over $4 a share and heading higher. At the point clinical trials start showing their results be prepared to pony up for shares. There is now an opportunity to invest in CNTX before the bulk of investors come up to speed concerning the potential market value of a pending CTIM-76 blockbuster. There are also other irons in the fire at Context Therapeutics to maintain shareholder excitement as well.

One such example is the strategic Partnership with Tyligand Biosciences for Onapristone extended release (ONA-XR) intended for use in hormone-driven breast, ovarian, and endometrial cancer. The partnership seems to be going according to pan. For immediate refresher see the following link. Tyligand Bioscience and Context Therapeutics Sign Strategic Development Agreement for Onapristone ER

Here is a link to the Onapristine ER trial (Oath) in the Journal of Clinical Oncology. Oath trial

Right now the shares of CNTX are held tight and likely have only a small pool available. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock as a buy. There is a growing consensus among some investors that the forecast is far to conservative with a $6.25-$15 range seeming a more realistic target within a year. Do some homework and see the opportunity before the masses. Like other biotech stocks, share value tends to get heated early when showing potential like this. Don't believe it? Look over Viking Therapeutics (VKTX) where it traded under $2 a share. CNTX isn't different; it's poised for the same type of breakout. Those Looking at the 5 year chart will have their eyes opened.

Investors should not forget Context Therapeutics announced on December 6, 2021 it had closed a previously announced placement of 5 million shares at a price of $6.25 per share. ThinkEquity acted as the sole placement agent and had no problem finding placement of those shares. There's a reason for that and that reason has not changed. The beat down of the share price is now over and referring back to Viking Therapeutics it had the same beat down before running up to over $25 a share. In fact on September 16, 2018 VKTX shares traded at $18.20 at the close of the day before being beaten down to $2.23 a share on June 5, 2022 only to break out and run to $24.27 on June 4, 2023. Even before that on July 30, 2017 VKTX shares closed at a mere 98 cents. The proven way to invest is buying in after the beatdown has occurred and when the facts on the ground for that investment have not changed. If you have invested that way you have better odds at picking a winner.

Concerning the science, CLDN6 differs from other claudins in that it's present in a mothers womb during a baby's development. After development CLDN6 is turned off. Cancer turns back on this claudin 6 to grow. CTIM-76 in development by CONTEXT Therapeutics attacks the turned on CLDN6. CTIM-76 is very specific at targeting CLND6. Other claudins exist that are needed in the body and targeting them could be harmful such as claudin 9 that is needed for hearing.

Analyst's Disclosure: I/we have a beneficial long position in the shares of CNTX either through stock ownership, options, or other derivatives.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.

Looking at the Context Therapeutics 5 year chart allows for a quick snapshot of the beginning turnaround in the share price .
👍️0
Biorat Biorat 6 months ago
Whether It’s Cloudy Or Sunny, You Should Be Buying Context Therapeutics (CNTX)

Oct. 3, 2023 4:29 PM ET| About: Context Therapeutics Inc. (CNTX), Includes: VKTX

Biotech Rat
Value, Special Situations, Momentum, Long/Short Equity

Summary
CTIM-76, a CLDN6 antagonist developed by Context Therapeutics, shows promise in redirecting T-cell activation towards tumor cells, enhancing safety.

The upcoming Society for Immunotherapy of Cancer meeting may highlight CTIM-76 as a potential blockbuster, leading to a surge in CNTX shares.

Analysts predict a conservative $4 share price or 164.90% increase in CNTX stock within 12 months, with a more realistic target range of $6.25-$15 explained here.

(Take a look at CONTEXT Therapeutics) CTIM-76 a CLDN6 antagonist that's in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This allows CTIM-76 to redirect T-cell activation away from where it would be harmful and enhances the safety profile vs its peers and what they are developing. There is an immense market given the absolute need for a high specificity to solid tumor cell treatment. $6.25-$15 a share is reasonable within 12 months. That's because the upcoming Society for Immunotherapy of Cancer meeting may alert investors to a potential blockbuster. CNTX shares could easily climb multiples higher given the tightly held float. By the time investors realize CTIM-76 is an exceptionally attractive investment CNTX shares will likely be trading over $4 a share and heading higher. At the point clinical trials start showing their results be prepared to pony up for shares. There is now an opportunity to invest in CNTX before the bulk of investors come up to speed concerning the potential market value of a pending CTIM-76 blockbuster. There are also other irons in the fire at Context Therapeutics to maintain shareholder excitement as well. One example being onapristone extended release (ONA-XR) for use in hormone-driven breast, ovarian, and endometrial cancer. Stay tuned for updates on the robust pipeline as fact checking is near completion. CNTX shares have been beaten down just like the shares of Viking Therapeutics (VKTX) had been before running up to over $25 a share.

Right now the shares of CNTX are held tight and likely have only a small pool available. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock as a buy. There is a growing consensus among some investors that the forecast is far to conservative with a $6.25-$15 range seeming a more realistic target within a year. Do some homework and see the opportunity before the masses. Like other biotech stocks, share value tends to get heated early when showing potential like this. Don't believe it? Look over Viking Therapeutics (VKTX) where it traded under $2 a share. CNTX isn't different; it's poised for the same type of breakout. Those Looking at the 5 year chart will have their eyes opened.

Investors should not forget Context Therapeutics announced on December 6, 2021 it had closed a previously announced placement of 5 million shares at a price of $6.25 per share. ThinkEquity acted as the sole placement agent and had no problem finding placement of those shares. There's a reason for that and that reason has not changed. The beat down of the share price is now over and referring back to Viking Therapeutics it had the same beat down before running up to over $25 a share. In fact on September 16, 2018 VKTX shares traded at $18.20 at the close of the day before being beaten down to $2.23 a share on June 5, 2022 only to break out and run to $24.27 on June 4, 2023. Even before that on July 30, 2017 VKTX shares closed at a mere 98 cents. The proven way to invest is buying in after the beatdown has occurred and when the facts on the ground for that investment have not changed. If you have invested that way you have better odds at picking a winner.

Concerning the science, CLDN6 differs from other claudins in that it's present in a mothers womb during a baby's development. After development CLDN6 is turned off. Cancer turns back on this claudin 6 to grow. CTIM-76 in development by CONTEXT Therapeutics attacks the turned on CLDN6. CTIM-76 is very specific at targeting CLND6. Other claudins exist that are needed in the body and targeting them could be harmful such as claudin 9 that is needed for hearing.

Due your own research and the wise will likely agree.

Disclosure: No recommendation or advice is being given as to whether any investment is suitable for a particular investor.
👍️0
Biorat Biorat 6 months ago
Whether It’s Cloudy Or Sunny, You Should Be Buying Context Therapeutics (CNTX)

(Take a look at CONTEXT Therapeutics) CTIM-76 a CLDN6 antagonist that's in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This allows CTIM-76 to redirect T-cell activation away from where it would be harmful and enhances the safety profile vs its peers and what they are developing. There is an immense market given the absolute need for a high specificity to solid tumor cell treatment. $6.25-$15 a share is reasonable within 12 months. That's because the upcoming Society for Immunotherapy of Cancer meeting may alert investors to a potential blockbuster. CNTX shares could easily climb multiples higher given the tightly held float. By the time investors realize CTIM-76 is an exceptionally attractive investment CNTX shares will likely be trading over $4 a share and heading higher. At the point clinical trials start showing their results be prepared to pony up for shares. There is now an opportunity to invest in CNTX before the bulk of investors come up to speed concerning the potential market value of a pending CTIM-76 blockbuster. There are also other irons in the fire at Context Therapeutics to maintain shareholder excitement as well. One example being onapristone extended release (ONA-XR) for use in hormone-driven breast, ovarian, and endometrial cancer. Stay tuned for updates on the robust pipeline as fact checking is near completion. CNTX shares have been beaten down just like the shares of Viking Therapeutics (VKTX) had been before running up to over $25 a share.


Right now the shares of CNTX are held tight and likely have only a small pool available. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock as a buy. There is a growing consensus among some investors that the forecast is far to conservative with a $6.25-$15 range seeming a more realistic target within a year. Do some homework and see the opportunity before the masses. Like other biotech stocks, share value tends to get heated early when showing potential like this. Don't believe it? Look over Viking Therapeutics (VKTX) where it traded under $2 a share. CNTX isn't different; it's poised for the same type of breakout. Those Looking at the 5 year chart will have their eyes opened.

Investors should not forget Context Therapeutics announced on December 6, 2021 it had closed a previously announced placement of 5 million shares at a price of $6.25 per share. ThinkEquity acted as the sole placement agent and had no problem finding placement of those shares. There's a reason for that and that reason has not changed. The beat down of the share price is now over and referring back to Viking Therapeutics it had the same beat down before running up to over $25 a share. In fact on September 16, 2018 VKTX shares traded at $18.20 at the close of the day before being beaten down to $2.23 a share on June 5, 2022 only to break out and run to $24.27 on June 4, 2023. Even before that on July 30, 2017 VKTX shares closed at a mere 98 cents. The proven way to invest is buying in after the beatdown has occurred and when the facts on the ground for that investment have not changed. If you have invested that way you have better odds at picking a winner.

Concerning the science, CLDN6 differs from other claudins in that it's present in a mothers womb during a baby's development. After development CLDN6 is turned off. Cancer turns back on this claudin 6 to grow. CTIM-76 in development by CONTEXT Therapeutics attacks the turned on CLDN6. CTIM-76 is very specific at targeting CLND6. Other claudins exist that are needed in the body and targeting them could be harmful such as claudin 9 that is needed for hearing.

Due your own research and the wise will likely agree.
👍️0
Biorat Biorat 6 months ago
Whether It’s Cloudy Or Sunny, You Should Be Buying Context Therapeutics (CNTX)

(Take a look at CONTEXT Therapeutics) CTIM-76 a CLDN6 antagonist is in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This allows CTIM-76 to redirect T-cell activation away from where it would be harmful and enhances the safety profile vs its peers and what they are developing. There is an immense market given the absolute need for a high specificity to solid tumor cell treatment. $6.25-$15 a share is reasonable within 12 months given the upcoming Society for Immunotherapy of Cancer meeting could alert investors to a potential blockbuster. CNTX shares could easily climb multiples higher given the tightly held float. By the time investors realize claudin 6 is an exceptionally attractive investment CNTX shares will likely be trading over $4 a share and heading higher. At the point clinical trails start showing their results be prepared to pony up for shares. There is opportunity to get in before the bulk of investors learn the potential market value of a pending CTIM-76 blockbuster. There are also other irons in the fire at Context Therapeutics to maintain share holder excitement as well. One example being onapristone extended release (ONA-XR) for use in hormone-driven breast, ovarian, and endometrial cancer. Stay tuned for updates on the robust pipeline as fact checking is near completion. CNTX shares have been beaten down just like the shares of Viking Therapeutics (VKTX) had been before running up to over $25 a share.


Right now the shares of CNTX are held tight and likely have only a small pool available. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock as a buy. There is a growing consensus among some investors that forecast is far to conservative with a $6.25-$15 range seeming a more realistic target within a year. Do some homework and see the opportunity before the masses. Things tend to get heated early with real potential like this. Don't believe it? Look over Viking Therapeutics (VKTX) where it traded under $2 a share. CNTX isn't different it's poised for the same type of breakout. Those Looking at the 5 year chart will have their eyes opened. 

Investors should not forget Context Therapeutics announced on December 6, 2021 it had closed a previously announced placement of 5 million shares at a price of $6.25 per share.  ThinkEquity acted as the sole placement agent and had no problem finding placement of those shares. There's a reason for that and that reason has not changed. The beat down of the share price is now over and referring back to  Viking Therapeutics it had the same beat down before running up to over $25 a share.  In fact on September 16, 2018 VKTX shares traded at $18.20 at the close of the day before being beaten down to $2.23 a share on June 5, 2022 only to breakout and run to $24.27 on June 4, 2023.  Even before that on July 30, 2017 VKTX shares closed at a mere 98 cents. The proven way to invest is buying in after the beat down has occurred and when the facts on the ground have not changed. If you have done that you have better odds at a winner.

Concerning the science, CLDN6 differs from other claudins in that it's present in a mothers womb during a babies development.  After development   CLDN6 is turned off. Cancer turns back on this claudin 6 to grow. CTIM-76 in development by CONTEXT Therapeutics attacks the turned on CLDN6.  CTIM-76 is very specific at targeting CLND6. Other claudins exist that are needed in the body and targeting them could be harmful such as claudin 9 that is needed for hearing.

Due your own research and the wise will should agree.
👍️0
Biorat Biorat 6 months ago
Whether It’s Cloudy Or Sunny, You Should Be Buying Context Therapeutics (CNTX)

(Take a look at CONTEXT Therapeutics) CTIM-76 a CLDN6 antagonist is in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This allows CTIM-76 to redirect T-cell activation away from where it would be harmful and enhances the safety profile vs its peers and what they are developing. There is an immense market given the absolute need for a high specificity to solid tumor cell treatment. $6.25-$15 a share is reasonable within 12 months given the upcoming Society for Immunotherapy of Cancer meeting could alert investors to a potential blockbuster. CNTX shares could easily climb multiples higher given the tightly held float. By the time investors realize claudin 6 is an exceptionally attractive investment CNTX shares will likely be trading over $4 a share and heading higher. At the point clinical trails start showing their results be prepared to pony up for shares. There is opportunity to get in before the bulk of investors learn the potential market value of a pending CTIM-76 blockbuster. There are also other irons in the fire at Context Therapeutics to maintain share holder excitement as well. Stay tuned for updates on the pipeline as fact checking is near completion. CNTX shares have been beaten down just like the shares of Viking Therapeutics (VKTX) had been before running up to over $25 a share.


Right now the shares of CNTX are held tight and likely have only a small pool available. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock as a buy. There is a growing consensus among some investors that forecast is far to conservative with a $6.25-$15 range seeming a more realistic target within a year. Do some homework and see the opportunity before the masses. Things tend to get heated early with real potential like this. Don't believe it? Look over Viking Therapeutics (VKTX) where it traded under $2 a share. CNTX isn't different it's poised for the same type of breakout. Those Looking at the 5 year chart will have their eyes opened. 

Investors should not forget Context Therapeutics announced on December 6, 2021 it had closed a previously announced placement of 5 million shares at a price of $6.25 per share.  ThinkEquity acted as the sole placement agent and had no problem finding placement of those shares. There's a reason for that and that reason has not changed. The beat down of the share price is now over and referring back to  Viking Therapeutics it had the same beat down before running up to over $25 a share.  In fact on September 16, 2018 VKTX shares traded at $18.20 at the close of the day before being beaten down to $2.23 a share on June 5, 2022 only to breakout and run to $24.27 on June 4, 2023.  Even before that on July 30, 2017 VKTX shares closed at a mere 98 cents. The proven way to invest is buying in after the beat down has occurred and when the facts on the ground have not changed. If you have done that you have better odds at a winner.

Concerning the science, CLDN6 differs from other claudins in that it's present in a mothers womb during a babies development.  After development   CLDN6 is turned off. Cancer turns back on this claudin 6 to grow. CTIM-76 in development by CONTEXT Therapeutics attacks the turned on CLDN6.  CTIM-76 is very specific at targeting CLND6. Other claudins exist that are needed in the body and targeting them could be harmful such as claudin 9 that is needed for hearing.

Due your own research and the wise will should agree.
👍️0
Biorat Biorat 6 months ago
Whether It’s Cloudy Or Sunny, You Should Be Buying Context Therapeutics (CNTX)

(Take a look at CONTEXT Therapeutics) CLDN6 is in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This allows CLDN6 to redirect T-cell activation away from where it would be harmful and enhances the safety profile vs its peers and what they are developing. There is an immense market given the absolute need for a high specificity to solid tumor cell treatment. $6-$15 a share is reasonable within 12 months given the upcoming Society for Immunotherapy of Cancer meeting could alert investors to a potential blockbuster. CNTX shares could easily climb multiples times higher given the tightly held float. By the time investors realize claudin 6 is an exceptionally attractive investment CNTX shares will likely be trading over $4 a share and heading higher. At the point clinical trails start showing their results be prepared to pony up for shares. There is opportunity to get in before the bulk of investors learn the potential market value of a pending CLND6 blockbuster. There are also other irons in the fire at Context Therapeutics to maintain share holder excitement as well. Stay tuned for updates on the pipeline as fact checking is near completion. CNTX stock has been beaten down just like the shares of Viking Therapeutics (VKTX) had been before running up to over $25 a share.


Right now the shares of CNTX are held tight and likely have only a small pool available. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock as a buy. There is a growing consensus among some investors that forecast is far to conservative with a $6-$15 range seeming a more realistic target within a year. Do some homework and see the opportunity before the masses. Things tend to get heated early with real potential like this. Don't believe it? Look over Viking Therapeutics (VKTX) where it traded under $2 a share. CNTX isn't different it's poised for the same type of breakout. Look at the 5 year chart and your eye will be open.
👍️0
Biorat Biorat 6 months ago


(Take a look at CNTX) CLDN6 is in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This allows CLDN6 to redirect T-cell activation away from where it would be harmful and enhances the safety profile vs its peers and what they are developing. There is an immense market given the absolute need for a high specificity to solid tumor cell treatment. $6-$15 a share is reasonable within 12 months given the upcoming Society for Immunotherapy of Cancer meeting will alert investors to the potential. CNTX shares could easily climb multiples times higher given the tightly held float. By the time investors realize claudin 6 is an exceptionally attractive investment CNTX shares will likely be trading over $4 a share and heading higher. At the point clinical trails start showing results be prepared to pony up for shares. There is opportunity to get in before the bulk of investors learn the market value of a pending CLND6 blockbuster. There are other irons in the fire at Context Therapeutics for share holder excitement as well. Stay tuned for udates on the pipeline as fact checking is near completion. CNTX stock had been beaten down just like the shares of Viking Thereputics(VKTX) Had been before running up to over $25 a share.

Right now the shares CNTX shares are held tight and only have a small pool available. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock stock as a buy. There is a growing consensus that forecast is far to conservative. $6-$15 seems a more realistic target within a year. Do some homework and see the opportunity before the masses. Things tend to get heated early with real potential like this.... Don't believe it? Look over VKTX where it traded under $2 a share. CNTX isn't different it's poised for the same type of breakout. Look at the 5 year chart and your eye will be open.
👍️0
Biorat Biorat 6 months ago
CNTX - CLDN6 is in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This will allow CLDN6 to redirect T-cell activation and enhance the safety profile. There is an immense market for and absolute need for high specificity to tumor cells and Context Therapeutics has got a good iron in the fire here. When investors realize claudin 6 is an exceptionally attractive target for big pharma CNTX shares will likely be trading well over $10 a share. At the point clinical trails start showing results be prepared to pony up for shares. Of course there will be opportunity to get in before the bulk of investors learn the market value of a pending success. There are some other irons in the fire here for CNTX share holders. Stay tuned CNTX was taken down just like VKTX shares for a different biotech company and before VKTX running up to the $25 area. More info is forthcoming after fact checking and review of Context Therapeutics pipeline. Right now the shares here are held tight and should really have a small pool being traded. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock stock as a buy. There is a growing consensus that forecast is far to conservative. $10 seems a more realistic target in that time frame. Longer term VKTX had nothing on CNTX. Do some homework and see the opportunity before the masses. Things do get heated early with real potential like this.... Don't believe it? Look over VKTX where this isn't it's first early move. CNTX isn't different.
👍️0
BooDog BooDog 11 months ago
$CNTX .65. Just needs to squeeze back over the $.

CNTX chart
👍️0
BooDog BooDog 12 months ago
Nice pop! Summertime's coming!!!
👍️0
BooDog BooDog 1 year ago
(1) The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 15, 2022.
5606 A $0.8742 (
https://ih.advfn.com/stock-market/NASDAQ/context-therapeutics-CNTX/stock-news/90223425/statement-of-changes-in-beneficial-ownership-4

This is my plan as well.

Still an open gap down to .70 though. Anything can happen. Especially if they can get the momentum that leads to regaining compliance.

CNTX daily
👍️0
vegasopc vegasopc 1 year ago
Thank you for all your DD. I can't believe someone would go to such lengths to deceive me.
👍️0
BooDog BooDog 1 year ago
I dug even deeper... The merger between Stemline & BERLIN-CHEMIE AG making them a subsidiary along with Context already in the mix making up part of the MENARINI Group was done back in 2020. Totally legit.

I would go on to say the only thing CNTX needs to do is get back in compliance with their listing requirements. Which, to me, looks completely possible. And SOON.

https://finance.yahoo.com/news/context-therapeutics-clinical-partner-stemline-123000936.html

https://www.sec.gov/Archives/edgar/data/1810515/000110465920071780/tm2021445d10_ex99a5e.htm

https://www.sec.gov/Archives/edgar/data/1810515/000110465920071780/tm2021445d10_sctota.htm

https://www.sec.gov/Archives/edgar/data/1264587/000110465920071879/tm2021445d15_s8pos.htm

There's more but I'm satisfied. There's still quite the gap to fill but it can save it for a rainy day. My alerts are set.
👍️0
vegasopc vegasopc 1 year ago
Now I'm wondering if my email is hacked. I received a notice from etrade yesterday that CNTX filed bankruptcy along with 8 pages of copies and now today I received a BK alert on another one of my stocks - seems fishy - especially since nobody else seems to know about it.
👍️0
BooDog BooDog 1 year ago
pipeline is strong and their cashflow is strong. 40M cash doesn't come close to what you're posting.

My search didn't come up with anything. I see merge potential if anything else.
👍️0
cary73 cary73 1 year ago
file bk??????
👍️0
vegasopc vegasopc 1 year ago
Shares are worthless. Filed BK.
👍️0
vegasopc vegasopc 1 year ago
I'm out. BK
👍️0
vegasopc vegasopc 1 year ago
$$$CNTX$$$ HOLY COW!!! $$$
👍️0
vegasopc vegasopc 1 year ago
$$$CNTX$$$ Very interesting start. Back in. $$$
👍️0
cary73 cary73 1 year ago
but can you read a piece of news...??? the drug is not from CNTX but from a subsidiary of Menarini.
The approved drug is in use in a phase 1 trial with a CNTX drug. There was no approval here.
The CEO was good at giving resonance to a piece of news that with CNTX marginally centered ... it was a good time to sell for those who had entered at 0.7 - 0.8 a good profit ..... there is no concrete here nothing
👍️0
BooDog BooDog 1 year ago
Exactly. Gap and trap and new bagholders. Pick your stop loss price and stick to it. Thinking this will see an offering by Friday.

But that's just my WAG.
👍️0
cash4 cash4 1 year ago
More sells than buys, now you know why it dropped right after the open.



Classic Gap'n Trap.
👍️0
Daytrader2013 Daytrader2013 1 year ago
Naked shorting from hell
👍️0
cash4 cash4 1 year ago
If this is the best it can do on great news, that means tomorrow it will be bellow a dollar, that's all she wrote.
👍️0
BooDog BooDog 1 year ago
I loaded 1.10. As much as I hate gaps this is solid news.
👍️0
TheFinalCD TheFinalCD 1 year ago
#unreal


hoe much you leave on that table $27

Message in reply to:
just finished MSGM now I'm here $$$$$
👍️0
Imott Imott 1 year ago
Had to load the dip. With such real good news I believe it has every chance to go into compliance. It is also nice to see the high of day broke the premarket high.
👍️0
reena969 reena969 1 year ago
look how big money traded MSGM. Maybe that's where most of FOMO went...lol
👍️0
cash4 cash4 1 year ago
Yeah...this is definitely going to chit.
👍️0
cash4 cash4 1 year ago
I'm sick of this corrupt market, that Halt managed to break the trend.
👍️0
Hercules1 Hercules1 1 year ago
$CNTX:

this should be trading above $3 already.

buyers have to overwhelm the shorts.

story is too damn big.
👍️0
cash4 cash4 1 year ago
who cares about charts with news like this ?
👍️0
cash4 cash4 1 year ago
This should be above $2 by now, but somehow it's going backwards.
👍️0
surf1944 surf1944 1 year ago
https://stockcharts.com/h-sc/ui?s=cntx&p=D&yr=0&mn=6&dy=0&id=p38090673899

https://www.barchart.com/stocks/quotes/cntx/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(20);SMA(50);SMA(100);SMA(200);CHKMF(20)&sym=SYSX&grid=1&height=210&studyheight=100

https://www.barchart.com/stocks/quotes/cntx/opinion

Open gap @ $.70 needs to close!
👍️0
Hercules1 Hercules1 1 year ago
$CNTX:

very small float considering the significant institutional ownership.


this can fly to $5 with this massive development:

Context Therapeutics' Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU(TM) (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer
7:30 am ET January 31, 2023 (Globe Newswire)
👍️0
cash4 cash4 1 year ago
Float 16 Mil, Market Cap 10 Mil, held by institutions 32%, 6% short, time to see the rainbow. $CNTX.
👍️0
vegasopc vegasopc 1 year ago
$$$CNTX$$$ Wow!!! $$$
👍️0
Invest-in-America Invest-in-America 1 year ago
CNTX: Hey, grab ME some more too, Homeboy!!

👍️0
cash4 cash4 1 year ago
More that twice the float has been traded already. $CNTX
👍️0
Hercules1 Hercules1 1 year ago
$CNTX:

you got that right bro.

this is beyond huge:

GlobeNewswireJanuary 31, 2023
First endocrine innovation in more than 20 years which has shown improved efficacy over standard-of-care treatments in patients with advanced breast cancer


FDA approval is in hand.


this is going to blow up sky high.

i am grabbing a few more.
👍️0
Invest-in-America Invest-in-America 1 year ago
CNTX: Incredible NEWS today, Herc!! (Breast Cancer one of the WORST diseases on this Planet, as we all know.)
👍️0
stokbrokin stokbrokin 1 year ago
Hey thats my old company I worked with!! Lenox Gltua peace stok
👍️0
Hercules1 Hercules1 1 year ago
$CNTX:

Context Therapeutics' Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU(TM) (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer
7:30 am ET January 31, 2023 (Globe Newswire) Print
GlobeNewswireJanuary 31, 2023


First endocrine innovation in more than 20 years which has shown improved efficacy over standard-of-care treatments in patients with advanced breast cancer
👍️0
Invest-in-America Invest-in-America 1 year ago
CNTX: "The Biggest-No-Brainer-In-The-History-Of-Mankind" --- and Wall Street, too!!



👍️0
Hercules1 Hercules1 1 year ago
$CNTX:


this is hitting $3 today.
👍️0

Your Recent History

Delayed Upgrade Clock